NIFTY Pharma climbs over 1.5%: Key things you need to know

The sector has been under pressure since the trade tariff talks began after US President Donald Trump took charge for his second term.

Trump has pointed out the high tariffs charged by India and other countries, including China and South Korea, and stated that the system is "not fair" to the United States.

The US is the largest importer of Indian pharma products, contributing a significant share of revenue to Indian drugmakers.

At present, there is no import duty on Indian pharmaceuticals in the US. But Trump announced that reciprocal tariffs would kick in on April 2, with the same tariffs imposed on imports from foreign nations as those imposed on US exports.

Imposing tariffs will increase the export cost for many pharma companies, thus affecting their margins as well.

Meanwhile, India's pharma exports are expected to double to $65 billion by 2030 and touch $350 billion in value terms by 2047, moving to the top five position globally by diversifying its product basket, according to a report from last week.

While India is the largest supplier of generic drugs globally, accounting for one in five generic drugs sold worldwide, the nation ranks 11th in terms of export value.

The sector rallied over 1.5% during the intraday trade as investors cheered the likely easing of trade tensions between the US and major trading partners.

At 2:20 PM, the sector was trading 1.58% higher at the 20,293.60 level.

Granules India, Gland Pharma, Cipla, Torrent Pharma, Laurus Lab, Zydus Life, Sun Pharma, Biocon, Aurobindo Pharma and Dr Reddy’s were the most contributing stocks in the sector, rising as much as 3.07% on the National Stock Exchange (NSE).

The Nifty index has lost 7.17% over a one-month period. Year-to-date, the sector is down 12.93%; however, it has gained 6.72% over a one-year period since March 6, 2025.

BSE Healthcare also surged over 1.3% to 39,769.42 level during the intraday on March 6.

Among the sector, Marksans Pharma, Themis Medicare, IOL Chemicals Pharma, Solara Active Pharma, and Indoco Remedies were the most gaining stocks, soaring as much as 6.68%.